J Studios
Becoming one of the first pharma majors to quantify earnings impact from the Trump administration’s newly imposed tariffs, Johnson & Johnson (NYSE:JNJ) on Tuesday projected a $400M headwind attributed to tariffs in 2025.
Speaking at JNJ’s earnings call, CFO Joseph Wolk